Akari Therapeutics Plc (AKTX) stock
AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.70−0.81 (-12.44%)
Close on Nov 17, 2026Market cap $11.10MP/E –Yield –
Earnings
Akari Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2024
–
EPS, Q2 FY2024
$0.00
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Akari Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | – | – | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 15, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Apr 16, 2025before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 19, 2024after the close | – | – | $0.00 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 16, 2024before the open | – | – | $0.00 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Akari Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Akari Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Akari Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- Update
- News
- News
- News
See a number that looks wrong?